Company intelligence / Profile preview

Blue Ribbon Bio

Hatfield Heath, Essex, United Kingdom

Ownership: Private
Development stage: Other

Overview

Blue Ribbon Bio's lead program focuses on the development of VAL201, a therapeutic peptide that has successfully completed a Phase 1/2 clinical trial in patients with metastatic prostate cancer, demonstrating safety and disease stabilization. The company is currently focused on optimizing this asset into a next-generation candidate to improve clinical outcomes and extend patent protection before re-entering the clinic.

Therapeutic areas: OncologyWomen's Health
Modalities: Peptides
Industry: Biotech

Partnerships

Cancer Research HorizonsInaphaea BioLabs

Beyond the preview

Go deeper on Blue Ribbon Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Ribbon Bio.

Explore the full profile